The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin.
Abstract
Although many trials have evaluated the severity and treatment of nausea and vomiting immediately after cisplatin administration, no studies have focused on vomiting occurring more than 24 hours after chemotherapy--delayed emesis. Two consecutive trials were undertaken to evaluate the incidence, course (trial 1), and severity (trial 2) of delayed nausea and emesis and to develop methods to study these conditions. Eighty-six patients receiving cisplatin (120 mg/m2) for the first time were entered. On the day of cisplatin treatment, all received intravenous (IV) metoclopramide (3 mg/kg X 2 doses) plus dexamethasone (20 mg IV X 1 dose) with either diphenhydramine (50 mg IV) or lorazepam (1.0 to 1.5 mg/m2). Sixty-two percent of patients experienced no vomiting during the 24 hours immediately after administration of cisplatin. Overall, 93% of studied patients experienced some degree of delayed nausea or vomiting from 24 to 120 hours after cisplatin. In trial 1, the incidence of delayed vomiting ranged from 21% to 61% and delayed nausea from 24% to 78% in 58 patients. The highest incidence of both delayed nausea and emesis occurred during the period from 48 to 72 hours after administration of cisplatin. Patients who had no emesis during the initial 24 hours after cisplatin were less likely to experience delayed emesis. The severity of delayed nausea and vomiting was evaluated in 28 patients in trial 2. The amount of delayed nausea and vomiting was assessed daily by patients using a visual analogue scale and by an observer rating. The highest nausea and vomiting scores were seen during the period from 48 to 72 hours after administration of cisplatin, with acceptable correlation between patient scores and observer ratings. Although the nausea and vomiting occurring 24 or more hours after cisplatin administration is not as severe as that seen during the initial 24 hours after administration of cisplatin in patients not receiving antiemetics, it is a common condition that merits both further study and specific treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Antiemetic Effect of Delta-9-Tetrahydrocannabinol in Patients Receiving Cancer Chemotherapy
Sallan, S. E., Zinberg, N. E., & Frei, E. (1975) · New England Journal of Medicine · doi:10.1056/nejm197510162931603 · Cited by 364
Cited by
Cohen, L., de Moor, C. A., Eisenberg, P., Ming, E. E., & Hu, H. (2007) · Supportive Care in Cancer · doi:10.1007/s00520-006-0173-z · Cited by 323
Lowenthal, R. M., & Eaton, K. (1996) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(05)70378-6 · Cited by 104
Metadata
- Authors
- Kris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O'Connell, J. P., Wertheim, M. S., & Kelsen, D. P.
- Venue
- Journal of Clinical Oncology
- Published
- 1985-10
- Volume
- 3
- Issue
- 10
- Pages
- 1379-1384
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154742149
- Cited by
- 336
- References
- 1
- FWCI
- 7.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. https://app.cochat.ai/papers/10.1200/jco.1985.3.10.1379
- The paper
- Kris, M. G., Gralla, R. J., Clark, R. A., Tyson, L. B., O'Connell, J. P., Wertheim, M. S., & Kelsen, D. P. (1985). Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1985.3.10.1379
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.